In a study comparing the antibody repertoire of individuals with severe myalgic encephalopathy/ chronic fatigue syndrome (ME/CFS) to that of healthy controls, the majority of individuals with CFS showed antibody responses to specific microbiome proteins. Such responses were largely absent in healthy controls, implicating immune reactions to the microbiome in the development of ME/CFS. Read More
Researchers from the University of California and affiliated organizations have published data from a study that focused on screening of factors involved in hepatic low-density lipoprotein receptor (LDLR) regulation, with the aim of identifying potential new therapeutic targets in cardiovascular disease.
Immunovant Inc. has announced a next-generation anti-FcRn, IMVT-1402, for autoimmune diseases. In animal studies, IMVT-1402 has shown deep IgG lowering, similar to the company's lead asset batoclimab, with no or minimal impact on albumin and low-density lipoprotein (LDL). Read More
Sengine Precision Medicine Inc. is conducting a study utilizing its high-throughput patient-derived organoid drug screening technology to identify novel therapeutic targets in progressive anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Read More
Type 1 diabetes is characterized by the destruction of insulin-producing β cells in the pancreas that leads to severe hyperglycemia if not treated. Read More
Cambridge Enterprise Ltd. has synthesized benzo[c][2,6]naphthyridine derivatives acting as casein kinase II isoform alpha prime (CK2α′) inhibitors reported to be useful for the treatment of cancer, diabetes, ischemia, neurodegeneration, viral infections cardiovascular and inflammatory disorders, among others. Read More
Verismo Therapeutics Inc. has received U.S. orphan drug designation from the FDA for Synkir-110 for the treatment of patients with mesothelin-expressing mesotheliomas. Read More
Deciduous Therapeutics Inc. has disclosed compounds with the ability to activate invariant natural killer T cells (iNKT) and that are reported to be useful for the treatment of obesity. Read More
Farnesoid X receptor (FXR) is a bile acid-activated receptor and in the gut it is mainly expressed in the ileum, promoting transcription of fibroblast growth factor-19 (FGF-19), a hormone with positive effects on energetic and glucose homeostasis. Read More
Viva Star Biosciences Ltd. has presented son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer. Read More
Hitgen Ltd. has divulged NUAK family SNF1-like kinase 1 (NUAK1) and/or NUAK family SNF1-like kinase 2 (NUAK2) inhibitors reported to be useful for the treatment of cancer. Read More
Wave Life Sciences Ltd. has highlighted progress with WVE-006, its preclinical Aimer (A-to-I RNA base editing) oligonucleotide candidate for the treatment of alpha-1 antitrypsin deficiency (AATD). Read More
Flare Therapeutics Inc. has synthesized peroxisome proliferator-activated receptor γ (PPARγ) inverse agonists reported to be useful for the treatment of bladder cancer. Read More
Researchers from Biomea Fusion Inc. presented preclinical data for the oral menin inhibitor, BMF-219, being developed for the treatment of diabetes. Read More
Researchers from the University of Zurich presented data from a study that aimed to investigate the impact of liver-specific apoptosis signal regulating kinase 1 (ASK1) overexpression on the development of high-fat diet (HFD)-induced obesity and impaired glucose metabolism. Read More
Almirall SA and Simcere Pharmaceutical Group Ltd. have entered into an exclusive licensing agreement for Simcere's IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM-0278. Read More
